Pavlos Msaouel, MD, PhD
Physician-scientist focused on rare kidney cancers and translational research
Summary
Work
Education
Projects
Writing
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
November 25, 2025Reports results of a phase II trial (NCT03274258) in RMC where combination anti-PD-1 and anti-CTLA-4 led to rapid progression in enrolled patients; identifies a tumor 'myeloid mimicry' program linked to hyperprogression and proposes p300/CEBPB axis as a therapeutic target based on preclinical models.
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling
October 1, 2025Integrated histopathologic, genomic, and transcriptomic profiling of RMC tissues identifying overexpressed surface proteins (TROP2, EPCAM, CLDN6, CDH6) and reporting clinical activity of sacituzumab govitecan in a small series.
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients
April 1, 2025Large single-center retrospective analysis describing demographics, presentation, metastatic patterns, and improving survival outcomes over time for patients with renal medullary carcinoma treated at MD Anderson.
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
March 1, 2025Identifies MUC16/CA-125 as an upregulated gene/protein in renal medullary carcinoma, prospectively validates serum CA-125 in patients (66% elevated in cohort) and correlates levels with metastatic burden; explores functional regulation by SMARCB1.